ClinicalTrials.gg
CompletedNCT01968109Updated Apr 6, 2026Results posted

An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors

A Phase 1/2 interventional study of Relatlimab and Nivolumab in Neoplasms by Site, sponsored by Bristol-Myers Squibb. Completed at 54 sites in 15 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-04-06.

Sponsored by Bristol-Myers Squibb · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
1,482
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 119 studies in Neoplasms by Site with a site in United States — 31 open to participants now, 44 under way, 7 of them phase 3. Neoplasms by Site · United States.

Enrollment
3rd of 102
1,482 · median 102
Started
2013
with 2 others
Phase 1/2
23 of 119
9 open now
Registered
29th of 119
by date
Lead sponsor
3 of 119
Bristol-Myers Squibb

Among the 119 studies in Neoplasms by Site with a site in United States, this one is the 3rd largest by enrollment of the 102 interventional ones that give a count, is one of 3 that started in 2013, is one of 23 in phase 1/2, and was the 29th registered.

Neoplasms by Site

208 studies on the registry are indexed under Neoplasms by Site; 53 are open to participants now.

Browse Neoplasms by Site studies →

Open to participants now

31 of the 119 studies in Neoplasms by Site with a site in United States are open now. Recruiting first, the newest first:

26 more — sign in →

All 31 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 51 Neoplasms by Site studies recruiting now, 40 (78%) set no upper age limit and 6 (12%) stop at 75 or younger; 7 take children under 18; 3 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 119 studies in Neoplasms by Site with a site in United States, or all of them as a file.
02

Study summary

The purpose of the study is to assess the safety, tolerability and effectiveness of experimental medication BMS-986016 administered alone and in combination with nivolumab in patients with solid tumors that have spread and/or cannot be removed by surgery.

The following tumor types are included in this study:

Non-Small Cell Lung Cancer (NSCLC), gastric cancer, hepatocellular carcinoma, renal cell carcinoma, bladder cancer, squamous cell carcinoma of the head and neck, and melanoma, that have NOT previously been treated with immunotherapy. NSCLC and melanoma that HAVE previously been treated with immunotherapy.

03

Conditions studied

  • Neoplasms by Site

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • For Dose escalation: subjects with cervical, ovarian, bladder and colorectal cancer (CRC), head and neck, gastric and hepatocellular cancer naive to immuno-oncology agents; melanoma and 1st line/2nd line NSCLC; Renal Cell Carcinoma naive to IO; NSCLC progressing while on or after therapy with anti-PD1/anti-PDL-1 and melanoma subjects progressed while-on or after treatment with anti-PD1 or anti-PDL1 with or without .
  • For Dose Expansion: all of the above in escalation except for cervical, ovarian, and CRC
  • Progressed, or been intolerant to, at least one standard treatment regimen, except for participants in 1st line cohorts.
  • performance status between 0 and 2
  • At least 1 lesion with at baseline
  • Availability of an existing tumor sample (and consent to allow pre-treatment tumor biopsy)

Exclusion criteria

Exclusion Criteria:

  • Primary central nervous system (CNS) tumors or solid tumors with as the only site of active disease
  • disease
  • Encephalitis, meningitis, or uncontrolled seizures in the year prior to
  • Uncontrolled CNS metastases

Other protocol defined inclusion/exclusion criteria could apply

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,482 participants (actual)

Study arms

  • Experimental
    Relatlimab

    Relatlimab (BMS-986016) specified dose on specified days

    Biological: Relatlimab

  • Experimental
    Relatlimab + Nivolumab

    Relatlimab (BMS-986016) + Nivolumab (BMS-936558) specified dose on specified days

    Biological: Relatlimab · Biological: Nivolumab

  • Experimental
    BMS-986213

    Relatlimab (BMS-986016) + Nivolumab (BMS-936558)

    Biological: BMS-986213

Interventions

  • BiologicalRelatlimab

    Also known as: BMS-986016, Anti-LAG-3 (Anti-Lymphocyte Activation Gene-3)

  • BiologicalNivolumab

    Also known as: Anti-PD-1 (Anti-Programmed-Death-1), BMS-936558

  • BiologicalBMS-986213

    Relatlimab + Nivolumab

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events, Deaths and Clinically Relevant Laboratory Abnormalities

    An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. SAEs is any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires inpatient hospitalization; results significant disability; or is a congenital anomaly/birth defect.

    Time frame: From first dose and within 135 days after last dose of study therapy (Up to approximately 82 months)

  2. Part C, D1, D2, E - Objective Response Rate Per BICR

    ORR is defined as the percentage of participants whose best overall response (BOR) is either CR or PR by blinded independent central review (BICR) per response evaluation criteria in solid tumors (RECIST) v1.1 based on Clopper-Pearson method. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\\< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum during the study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

    Time frame: From first dose to the date of first objectively documented progression, per RECIST v1.1, or death due to any cause, whichever occurred first (up to approximately 127 months)

  3. Part C, D1, D2, E - Disease Control Rate (DCR) Per BICR

    Disease Control Rate (DCR) (as per Recists v1.1) is defined as the percentage of randomized participants who achieve a BOR of confirmed CR, confirmed PR, or stable disease (SD), based on BICR assessments divided by the number of all randomized participants. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\\< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum during the study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

    Time frame: From first dose to the date of first objectively documented progression, per RECIST v1.1, or death due to any cause, whichever occurred first (up to approximately 127 months)

  4. Part C, D1, D2, E - Duration of Response (DOR) Per BICR

    DOR for a participant with a best overall response (BOR) of CR or PR is defined as the time between the date of first response and the date of the first objectively documented tumor progression by blinded independent central review (BICR) per response evaluation criteria in solid tumors (RECIST) v1.1 or death, whichever occurs first. Median computed using Kaplan-Meier method. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\\< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum during the study (this includes the baseline sum). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

    Time frame: From first dose to the date of first objectively documented progression, per RECIST v1.1, or death due to any cause, whichever occurred first (up to approximately 127 months)

  5. Part D1: Number of Participants With Adverse Events in the Broad Scope Standardized MedDRA (SMQ) Anaphylactic Reaction Occurring Within 2 Days of Any Doses of Study Therapy

    An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.

    Time frame: From first dose and within 2 days of first dose of study therapy

  6. Part C, D1, D2, E - Objective Response Rate Per BICR

    ORR is defined as the percentage of participants whose best overall response (BOR) is either CR or PR by blinded independent central review (BICR) per response evaluation criteria in solid tumors (RECIST) v1.1 based on Clopper-Pearson method. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\\< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum during the study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

    Time frame: From first dose (Day 1) and up to 97 months

Secondary outcomes

  1. Part C, D1 and D2: Progression-Free Survival (PFS) Rate Per BICR

    Progression Free Survival Rates at 12 months is defined as the proportion of participants who achieve PFS at 12 months. PFS for a participant is defined as the time from randomization date to the date of first objectively documented disease progression by blinded independent central review (BICR) per response evaluation criteria in solid tumors (RECIST) v1.1 or death due to any cause, whichever occurs first. Based on Kaplan-Meier Estimates. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum during the study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

    Time frame: Up to 12 months

  2. Part D1 and D2: Overall Survival (OS) at 12 and 24 Months

    Overall survival at 1 year, and 2 years is defined as the proportion of participants who are alive at 1 year, and 2 years. Based on Kaplan-Meier Estimates.

    Time frame: At 12 and 24 months after first dose

  3. Part C, D1, D2, E - Objective Response Rate Per Investigator

    ORR is defined as the percentage of participants whose best overall response (BOR) is either CR or PR by investigator per response evaluation criteria in solid tumors (RECIST) v1.1 based on Clopper-Pearson method. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\\< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum during the study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

    Time frame: From first dose to the date of first objectively documented progression, per RECIST v1.1, or death due to any cause, whichever occurred first (up to approximately 127 months)

  4. Part C, D1, D2, E - Disease Control Rate (DCR) Per Investigator

    Disease Control Rate (DCR) (as per Recists v1.1) is defined as the percentage of randomized participants who achieve a BOR of confirmed CR, confirmed PR, or stable disease (SD), based on BICR assessments divided by the number of all randomized participants. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\\< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum during the study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

    Time frame: From first dose to the date of first objectively documented progression, per RECIST v1.1, or death due to any cause, whichever occurred first (up to approximately 127 months)

  5. Part C, D1, D2, E - Duration of Response (DOR) Per Investigator

    DOR for a participant with a best overall response (BOR) of CR or PR is defined as the time between the date of first response and the date of the first objectively documented tumor progression by investigator per response evaluation criteria in solid tumors (RECIST) v1.1 or death, whichever occurs first. Median computed using Kaplan-Meier method. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\\< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum during the study (this includes the baseline sum). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

    Time frame: From first dose to the date of first objectively documented progression, per RECIST v1.1, or death due to any cause, whichever occurred first (up to approximately 127 months)

  6. Part C, D1 and D2: Progression-Free Survival (PFS) Rate Per Investigator

    Progression Free Survival Rates up to 12 months is defined as the proportion of participants who achieve PFS up to 12 months. PFS for a participant is defined as the time from randomization date to the date of first objectively documented disease progression by investigator per response evaluation criteria in solid tumors (RECIST) v1.1 or death due to any cause, whichever occurs first. Based on Kaplan-Meier Estimates. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum during the study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

    Time frame: Up to 12 months

  7. Number of Participants With Positive Anti Drug Antibodies

    Blood samples were collected to assess anti-drug antibodies.

    Time frame: predose, and 4-hour post-dose of relatlimab on Cycle 1 Day 1 and Cycle 3 Day 1 (Each cycle consist of 28 days)

  8. Part A, A/A1, and B: Number of Participants With Clinically Relevant QT Prolongation

    Abnormal electrocardiogram parameter included QT prolongation.

    Time frame: predose, and 4-hour post-dose of relatlimab on Cycle 1 Day 1 and Cycle 3 Day 1 (Each cycle consist of 28 days)

  9. Maximum Observed Concentration (Cmax) of BMS-986016 (Relatlimab)

    Blood samples were collected for assessment of pharmacokinetic parameter of BMS-986016 (relatlimab).

    Time frame: Day 1 of Cycle 1 and 3

  10. Time to Maximum Observed Concentration (Tmax) of BMS-986016 (Relatlimab)

    Blood samples were collected for assessment of pharmacokinetic parameter of BMS-986016 (relatlimab).

    Time frame: Day 1 of Cycle 1 and 3 (Each cycle consist of 28 days).

  11. Area Under the Concentration-time Curve in One Dosing Interval (AUCtau) of BMS-986016 (Relatlimab)

    Blood samples were collected for assessment of pharmacokinetic parameter of BMS-986016 (relatlimab).

    Time frame: Day 1 of Cycle 1 and 3 (Each cycle consist of 28 days).

  12. Part A/A1, B, C, D1, D2 and E: Trough Observed Concentration (Ctrough) of BMS-986016 (Relatlimab)

    Blood samples were collected for assessment of pharmacokinetic parameter of BMS-986016 (relatlimab). Ctrough is defined as the lowest concentration of drug in the blood immediately before the next dose is administered. Ctrough was only assessed for arm Part A/A1, B, C, D1, D2 and E as pre-specified.

    Time frame: Day 1 of Cycle 3 (Each cycle consist of 28 days)

  13. Part A/A1, B, CTotal Body Clearance (CLT) of BMS-986016 (Relatlimab)

    Blood samples were collected for assessment of pharmacokinetic parameter of BMS-986016 (relatlimab). CLT was only assessed for arm Part A/A1, B, C as pre-specified.

    Time frame: Day 1 of Cycle 3 (Each cycle consist of 28 days).

  14. Part A/A1, B, C AUC Accumulation Index AI_AUC of BMS-986016 (Relatlimab)

    Blood samples were collected for assessment of pharmacokinetic parameter of BMS-986016 (relatlimab). AUC Accumulation Index is a pharmacokinetic metric used to quantify how much a drug accumulates in the body after repeated dosing compared to a single dose. It is ratio of AUC Steady State (AUCss) and AUC1. AUCₛₛ is the area under the plasma concentration-time curve during a dosing interval at steady state (after repeated doses). AUC₁ is the area under the curve after a single dose. Only assessed for arm Part A/A1, B, C as pre-specified.

    Time frame: Day 1 of Cycle 3 (Each cycle consist of 28 days)

07

Results

Posted Jan 6, 2026

Participant flow

Participant flow — Overall Study
MilestoneBMS-986016 (Relatlimab) Monotherapy 20 Milligram (mg) (Part A)BMS-986016 (Relatlimab) Monotherapy 80 Milligram (mg) (Part A)BMS-986016 (Relatlimab) Monotherapy 240 Milligram (mg) (Part A)BMS-986016 (Relatlimab) Monotherapy 800 Milligram (mg) (Part A/A1)Combination-Escalation-BMS-986016 (Relatlimab)/Nivolumab (20 mg/80 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (20 mg/240 mg (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (80 mg/240 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (160 mg/240 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (240 mg/240 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (160 mg/480 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (240 mg/480 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (320 mg/480 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (480 mg/480 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (960 mg/480 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (1440 mg/480 mg) (Part B)NSCLC IO Naive-80/240 (Part C)MEL 1L-80/240 (Part C)RCC IO Naive-80/240 (Part C)SCCHN IO Naive-80/240 (Part C)HCC IO Naive-80/240 (Part C)Gastric IO Naive-80/240 (Part C)Bladder IO Naive-160/480 (Part C)NSCLC Prior IO-80/240 (Part C)MEL Prior IO - 80/240 (Part C)MEL Prior IO Rf-80/240 Q2W (Part D1 Coad)MEL Prior IO Rf-160/480 Q4W (Part D1 Coad)MEL Prior IO Rf-160/480 (Part D1 FDC)MEL Prior IO Rf-160/480 (Part D2)MEL 1L-160/480 (Part E)MEL 1L-480/480 (Part E)MEL Prior IO rf - 480/480 (Part E)
Started54412798888887171924662665639437571511898382164777795
Completed0000000000000000000000000000000
Not completed54412798888887171924662665639437571511898382164777795
Withdrew: Disease progression4439566645847141413342054467725471251546366137352371
Withdrew: Subject request to discontinue study treatment10001111000000011110303473238123
Withdrew: Study drug toxicity0012111021020224113496438983915219
Withdrew: Subject withdrew consent0000000100000000001111003214011
Withdrew: Adverse event unrelated to study drug0000000012010102404323415622343
Withdrew: Completed treatment as per protocol000001001000000310111210105012001
Withdrew: Other reasons000100000001003110011200515511104
Withdrew: Maximum clinical benefit0000000000000000510210001022562
Withdrew: Subject no longer meets study criteria0000000000000000000010030000000
Withdrew: Death0000000000000000000001000000001

Outcome measures

PrimaryNumber of Participants With Adverse Events, Deaths and Clinically Relevant Laboratory Abnormalities

An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. SAEs is any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires inpatient hospitalization; results significant disability; or is a congenital anomaly/birth defect.

Time frame:
From first dose and within 135 days after last dose of study therapy (Up to approximately 82 months)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events, Deaths and Clinically Relevant Laboratory Abnormalities
ParticipantsBMS-986016 (Relatlimab) Monotherapy 20 Milligram (mg) (Part A)BMS-986016 (Relatlimab) Monotherapy 80 Milligram (mg) (Part A)BMS-986016 (Relatlimab) Monotherapy 240 Milligram (mg) (Part A)BMS-986016 (Relatlimab) Monotherapy 800 Milligram (mg) (Part A/A1)Combination-Escalation-BMS-986016 (Relatlimab)/Nivolumab (20 mg/80 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (20 mg/240 mg (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (80 mg/240 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (160 mg/240 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (240 mg/240 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (160 mg/480 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (240 mg/480 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (320 mg/480 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (480 mg/480 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (960 mg/480 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (1440 mg/480 mg) (Part B)NSCLC IO Naive-80/240 (Part C)MEL 1L-80/240 (Part C)RCC IO Naive-80/240 (Part C)SCCHN IO Naive-80/240 (Part C)HCC IO Naive-80/240 (Part C)Gastric IO Naive-80/240 (Part C)Bladder IO Naive-160/480 (Part C)NSCLC Prior IO-80/240 (Part C)MEL Prior IO - 80/240 (Part C)MEL Prior IO Rf-80/240 Q2W (Part D1 Coad)MEL Prior IO Rf-160/480 Q4W (Part D1 Coad)MEL Prior IO Rf-160/480 (Part D1 FDC)MEL Prior IO Rf-160/480 (Part D2)MEL 1L-160/480 (Part E)MEL 1L-480/480 (Part E)MEL Prior IO rf - 480/480 (Part E)
Adverse Events54412798887887171923622664639435571401868180161767793
Serious Adverse Events533757667556310121538174449692836981185849113494770
AEs leading to discontinuation102313203203043614919201810153223181023192714
Deaths53411576768664161317371757498029541161557164135273282
Clinically Relevant Laboratory Abnormalities0000000000000000000000000000000
Death due to Disease53311576658534141214321748437429481121386759127242773
Death due to unknown reason00100001001202003016302312123131
Death due to study drug toxicity0000000010000000002000100000010
Death due to other reasons0000000000010013206030315335212
PrimaryPart C, D1, D2, E - Objective Response Rate Per BICR

ORR is defined as the percentage of participants whose best overall response (BOR) is either CR or PR by blinded independent central review (BICR) per response evaluation criteria in solid tumors (RECIST) v1.1 based on Clopper-Pearson method. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\\< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum during the study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

Time frame:
From first dose to the date of first objectively documented progression, per RECIST v1.1, or death due to any cause, whichever occurred first (up to approximately 127 months)
Reported as:
Number · percentage of participants
Part C, D1, D2, E - Objective Response Rate Per BICR
percentage of participantsNSCLC IO Naive-80/240 (Part C)MEL 1L-80/240 (Part C)RCC IO Naive-80/240 (Part C)SCCHN IO Naive-80/240 (Part C)HCC IO Naive-80/240 (Part C)Gastric IO Naive-80/240 (Part C)Bladder IO Naive-160/480 (Part C)NSCLC Prior IO-80/240 (Part C)MEL Prior IO - 80/240 (Part C)MEL Prior IO Rf-80/240 Q2W (Part D1 Coad)MEL Prior IO Rf-160/480 Q4W (Part D1 Coad)MEL Prior IO Rf-160/480 (Part D1 FDC)MEL Prior IO Rf-160/480 (Part D2)MEL 1L-160/480 (Part E)MEL 1L-480/480 (Part E)MEL Prior IO rf - 480/480 (Part E)
Part C, D1, D2, E - Objective Response Rate Per BICR29.2 (12.6 to 51.1)47.0 (34.6 to 59.7)15.4 (4.4 to 34.9)15.4 (7.6 to 26.5)15.9 (7.9 to 27.3)8.6 (3.8 to 16.2)30.6 (16.3 to 48.1)5.3 (1.1 to 14.6)10.7 (6.2 to 16.7)12.4 (8.0 to 18.0)7.2 (2.7 to 15.1)19.5 (11.6 to 29.7)9.1 (5.2 to 14.6)48.7 (37.0 to 60.4)61.0 (49.2 to 72.0)10.6 (5.2 to 18.7)
PrimaryPart C, D1, D2, E - Disease Control Rate (DCR) Per BICR

Disease Control Rate (DCR) (as per Recists v1.1) is defined as the percentage of randomized participants who achieve a BOR of confirmed CR, confirmed PR, or stable disease (SD), based on BICR assessments divided by the number of all randomized participants. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\\< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum during the study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

Time frame:
From first dose to the date of first objectively documented progression, per RECIST v1.1, or death due to any cause, whichever occurred first (up to approximately 127 months)
Reported as:
Number · percentage of participants
Part C, D1, D2, E - Disease Control Rate (DCR) Per BICR
percentage of participantsNSCLC IO Naive-80/240 (Part C)MEL 1L-80/240 (Part C)RCC IO Naive-80/240 (Part C)SCCHN IO Naive-80/240 (Part C)HCC IO Naive-80/240 (Part C)Gastric IO Naive-80/240 (Part C)Bladder IO Naive-160/480 (Part C)NSCLC Prior IO-80/240 (Part C)MEL Prior IO - 80/240 (Part C)MEL Prior IO Rf-80/240 Q2W (Part D1 Coad)MEL Prior IO Rf-160/480 Q4W (Part D1 Coad)MEL Prior IO Rf-160/480 (Part D1 FDC)MEL Prior IO Rf-160/480 (Part D2)MEL 1L-160/480 (Part E)MEL 1L-480/480 (Part E)MEL Prior IO rf - 480/480 (Part E)
Part C, D1, D2, E - Disease Control Rate (DCR) Per BICR50.0 (29.1 to 70.9)59.1 (46.3 to 71.0)46.2 (26.6 to 66.6)49.2 (36.6 to 61.9)50.8 (37.9 to 63.6)25.8 (17.3 to 35.9)44.4 (27.9 to 61.9)40.4 (27.6 to 54.2)38.0 (30.2 to 46.3)39.2 (32.2 to 46.7)32.5 (22.6 to 43.7)50.0 (38.7 to 61.3)37.8 (30.4 to 45.7)61.8 (50.0 to 72.8)68.8 (57.3 to 78.9)39.4 (29.4 to 50.0)
PrimaryPart C, D1, D2, E - Duration of Response (DOR) Per BICR

DOR for a participant with a best overall response (BOR) of CR or PR is defined as the time between the date of first response and the date of the first objectively documented tumor progression by blinded independent central review (BICR) per response evaluation criteria in solid tumors (RECIST) v1.1 or death, whichever occurs first. Median computed using Kaplan-Meier method. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\\< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum during the study (this includes the baseline sum). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

Time frame:
From first dose to the date of first objectively documented progression, per RECIST v1.1, or death due to any cause, whichever occurred first (up to approximately 127 months)
Reported as:
Median · months
Part C, D1, D2, E - Duration of Response (DOR) Per BICR
monthsNSCLC IO Naive-80/240 (Part C)MEL 1L-80/240 (Part C)RCC IO Naive-80/240 (Part C)SCCHN IO Naive-80/240 (Part C)HCC IO Naive-80/240 (Part C)Gastric IO Naive-80/240 (Part C)Bladder IO Naive-160/480 (Part C)NSCLC Prior IO-80/240 (Part C)MEL Prior IO - 80/240 (Part C)MEL Prior IO Rf-80/240 Q2W (Part D1 Coad)MEL Prior IO Rf-160/480 Q4W (Part D1 Coad)MEL Prior IO Rf-160/480 (Part D1 FDC)MEL Prior IO Rf-160/480 (Part D2)MEL 1L-160/480 (Part E)MEL 1L-480/480 (Part E)MEL Prior IO rf - 480/480 (Part E)
Part C, D1, D2, E - Duration of Response (DOR) Per BICR40.4 (6.4 to 51.4)NA (1.9 to 65.6)NA (3.0 to 58.2)27.9 (3.7 to 28.6)54.6 (11.7 to 75.5)35.1 (6.8 to 62.1)18.7 (5.6 to 57.9)8.6 (5.6 to 9.9)21.1 (3.2 to 57.5)24.5 (3.6 to 66.5)29.4 (12.6 to 38.8)20.7 (5.5 to 59.1)12.8 (1.3 to 55.0)NA (5.6 to 53.2)NA (6.5 to 49.9)NA (2.0 to 51.8)
PrimaryPart D1: Number of Participants With Adverse Events in the Broad Scope Standardized MedDRA (SMQ) Anaphylactic Reaction Occurring Within 2 Days of Any Doses of Study Therapy

An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.

Time frame:
From first dose and within 2 days of first dose of study therapy
Reported as:
Count of participants · Participants
Part D1: Number of Participants With Adverse Events in the Broad Scope Standardized MedDRA (SMQ) Anaphylactic Reaction Occurring Within 2 Days of Any Doses of Study Therapy
ParticipantsMEL Prior IO Rf-80/240 Q2W (Part D1 Coad)MEL Prior IO Rf-160/480 Q4W (Part D1 Coad)MEL Prior IO Rf-160/480 (Part D1 FDC)
Pruritus1422
Rash1134
Erythema231
Rash erythematous101
Rash pruritic100
Urticaria101
Cough834
Dyspnea622
Wheezing100
Hypotension221
Flushing100
PrimaryPart C, D1, D2, E - Objective Response Rate Per BICR

ORR is defined as the percentage of participants whose best overall response (BOR) is either CR or PR by blinded independent central review (BICR) per response evaluation criteria in solid tumors (RECIST) v1.1 based on Clopper-Pearson method. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\\< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum during the study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

Time frame:
From first dose (Day 1) and up to 97 months
Reported as:
Number · percentage of participants
Part C, D1, D2, E - Objective Response Rate Per BICR
percentage of participantsNSCLC IO Naive-80/240 (Part C)MEL 1L-80/240 (Part C)RCC IO Naive-80/240 (Part C)SCCHN IO Naive-80/240 (Part C)HCC IO Naive-80/240 (Part C)Gastric IO Naive-80/240 (Part C)Bladder IO Naive-160/480 (Part C)NSCLC Prior IO-80/240 (Part C)MEL Prior IO - 80/240 (Part C)MEL Prior IO Rf-80/240 Q2W (Part D1 Coad)MEL Prior IO Rf-160/480 Q4W (Part D1 Coad)MEL Prior IO Rf-160/480 (Part D1 FDC)MEL Prior IO Rf-160/480 (Part D2)MEL 1L-160/480 (Part E)MEL 1L-480/480 (Part E)MEL Prior IO rf - 480/480 (Part E)
Part C, D1, D2, E - Objective Response Rate Per BICR29.2 (12.6 to 51.1)47.0 (34.6 to 59.7)15.4 (4.4 to 34.9)15.4 (7.6 to 26.5)15.9 (7.9 to 27.3)8.6 (3.8 to 16.2)30.6 (16.3 to 48.1)5.3 (1.1 to 14.6)10.7 (6.2 to 16.7)12.4 (8.0 to 18.0)7.2 (2.7 to 15.1)19.5 (11.6 to 29.7)9.1 (5.2 to 14.6)48.7 (37.0 to 60.4)61.0 (49.2 to 72.0)10.6 (5.2 to 18.7)
SecondaryPart C, D1 and D2: Progression-Free Survival (PFS) Rate Per BICR

Progression Free Survival Rates at 12 months is defined as the proportion of participants who achieve PFS at 12 months. PFS for a participant is defined as the time from randomization date to the date of first objectively documented disease progression by blinded independent central review (BICR) per response evaluation criteria in solid tumors (RECIST) v1.1 or death due to any cause, whichever occurs first. Based on Kaplan-Meier Estimates. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum during the study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

Time frame:
Up to 12 months
Reported as:
Number · proportion of participants
Part C, D1 and D2: Progression-Free Survival (PFS) Rate Per BICR
proportion of participantsNSCLC IO Naive-80/240 (Part C)MEL 1L-80/240 (Part C)RCC IO Naive-80/240 (Part C)SCCHN IO Naive-80/240 (Part C)HCC IO Naive-80/240 (Part C)Gastric IO Naive-80/240 (Part C)Bladder IO Naive-160/480 (Part C)NSCLC Prior IO-80/240 (Part C)MEL Prior IO - 80/240 (Part C)MEL Prior IO Rf-80/240 Q2W (Part D1 Coad)MEL Prior IO Rf-160/480 Q4W (Part D1 Coad)MEL Prior IO Rf-160/480 (Part D1 FDC)MEL Prior IO Rf-160/480 (Part D2)
Part C, D1 and D2: Progression-Free Survival (PFS) Rate Per BICR0.28 (0.11 to 0.47)0.48 (0.35 to 0.60)0.29 (0.12 to 0.48)0.17 (0.08 to 0.27)0.24 (0.14 to 0.36)0.09 (0.04 to 0.16)0.25 (0.12 to 0.41)0.11 (0.04 to 0.21)0.13 (0.08 to 0.20)0.22 (0.16 to 0.29)0.18 (0.11 to 0.28)0.29 (0.20 to 0.40)0.16 (0.10 to 0.23)
SecondaryPart D1 and D2: Overall Survival (OS) at 12 and 24 Months

Overall survival at 1 year, and 2 years is defined as the proportion of participants who are alive at 1 year, and 2 years. Based on Kaplan-Meier Estimates.

Time frame:
At 12 and 24 months after first dose
Reported as:
Number · proportion of participants
Part D1 and D2: Overall Survival (OS) at 12 and 24 Months
proportion of participantsMEL Prior IO Rf-80/240 Q2W (Part D1 Coad)MEL Prior IO Rf-160/480 Q4W (Part D1 Coad)MEL Prior IO Rf-160/480 (Part D1 FDC)MEL Prior IO Rf-160/480 (Part D2)
12 months0.56 (0.49 to 0.63)0.51 (0.39 to 0.61)0.57 (0.46 to 0.67)0.59 (0.52 to 0.67)
24 months0.30 (0.24 to 0.37)0.31 (0.21 to 0.41)0.37 (0.27 to 0.48)0.38 (0.31 to 0.45)
SecondaryPart C, D1, D2, E - Objective Response Rate Per Investigator

ORR is defined as the percentage of participants whose best overall response (BOR) is either CR or PR by investigator per response evaluation criteria in solid tumors (RECIST) v1.1 based on Clopper-Pearson method. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\\< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum during the study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

Time frame:
From first dose to the date of first objectively documented progression, per RECIST v1.1, or death due to any cause, whichever occurred first (up to approximately 127 months)
Reported as:
Number · percentage of participants
Part C, D1, D2, E - Objective Response Rate Per Investigator
percentage of participantsNSCLC IO Naive-80/240 (Part C)MEL 1L-80/240 (Part C)RCC IO Naive-80/240 (Part C)SCCHN IO Naive-80/240 (Part C)HCC IO Naive-80/240 (Part C)Gastric IO Naive-80/240 (Part C)Bladder IO Naive-160/480 (Part C)NSCLC Prior IO-80/240 (Part C)MEL Prior IO - 80/240 (Part C)MEL Prior IO Rf-80/240 Q2W (Part D1 Coad)MEL Prior IO Rf-160/480 Q4W (Part D1 Coad)MEL Prior IO Rf-160/480 (Part D1 FDC)MEL Prior IO Rf-160/480 (Part D2)MEL 1L-160/480 (Part E)MEL 1L-480/480 (Part E)MEL Prior IO rf - 480/480 (Part E)
Part C, D1, D2, E - Objective Response Rate Per Investigator41.7 (22.1 to 63.4)50.0 (37.4 to 62.6)11.5 (2.4 to 30.2)15.4 (7.6 to 26.5)15.9 (7.9 to 27.3)15.1 (8.5 to 24.0)36.1 (20.8 to 53.8)5.3 (1.1 to 14.6)8.7 (4.7 to 14.4)12.9 (8.4 to 18.6)8.4 (3.5 to 16.6)17.1 (9.7 to 27.0)9.1 (5.2 to 14.6)46.1 (34.5 to 57.9)61.0 (49.2 to 72.0)16.0 (9.2 to 25.0)
SecondaryPart C, D1, D2, E - Disease Control Rate (DCR) Per Investigator

Disease Control Rate (DCR) (as per Recists v1.1) is defined as the percentage of randomized participants who achieve a BOR of confirmed CR, confirmed PR, or stable disease (SD), based on BICR assessments divided by the number of all randomized participants. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\\< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum during the study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

Time frame:
From first dose to the date of first objectively documented progression, per RECIST v1.1, or death due to any cause, whichever occurred first (up to approximately 127 months)
Reported as:
Number · percentage of participants
Part C, D1, D2, E - Disease Control Rate (DCR) Per Investigator
percentage of participantsNSCLC IO Naive-80/240 (Part C)MEL 1L-80/240 (Part C)RCC IO Naive-80/240 (Part C)SCCHN IO Naive-80/240 (Part C)HCC IO Naive-80/240 (Part C)Gastric IO Naive-80/240 (Part C)Bladder IO Naive-160/480 (Part C)NSCLC Prior IO-80/240 (Part C)MEL Prior IO - 80/240 (Part C)MEL Prior IO Rf-80/240 Q2W (Part D1 Coad)MEL Prior IO Rf-160/480 Q4W (Part D1 Coad)MEL Prior IO Rf-160/480 (Part D1 FDC)MEL Prior IO Rf-160/480 (Part D2)MEL 1L-160/480 (Part E)MEL 1L-480/480 (Part E)MEL Prior IO rf - 480/480 (Part E)
Part C, D1, D2, E - Disease Control Rate (DCR) Per Investigator62.5 (40.6 to 81.2)62.1 (49.3 to 73.8)46.2 (26.6 to 66.6)50.8 (38.1 to 63.4)54.0 (40.9 to 66.6)32.3 (22.9 to 42.7)50.0 (32.9 to 67.1)38.6 (26.0 to 52.4)42.7 (34.6 to 51.0)44.1 (36.8 to 51.5)45.8 (34.8 to 57.1)45.1 (34.1 to 56.5)39.6 (32.1 to 47.6)55.3 (43.4 to 66.7)68.8 (57.3 to 78.9)43.6 (33.4 to 54.2)
SecondaryPart C, D1, D2, E - Duration of Response (DOR) Per Investigator

DOR for a participant with a best overall response (BOR) of CR or PR is defined as the time between the date of first response and the date of the first objectively documented tumor progression by investigator per response evaluation criteria in solid tumors (RECIST) v1.1 or death, whichever occurs first. Median computed using Kaplan-Meier method. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\\< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum during the study (this includes the baseline sum). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

Time frame:
From first dose to the date of first objectively documented progression, per RECIST v1.1, or death due to any cause, whichever occurred first (up to approximately 127 months)
Reported as:
Median · months
Part C, D1, D2, E - Duration of Response (DOR) Per Investigator
monthsNSCLC IO Naive-80/240 (Part C)MEL 1L-80/240 (Part C)RCC IO Naive-80/240 (Part C)SCCHN IO Naive-80/240 (Part C)HCC IO Naive-80/240 (Part C)Gastric IO Naive-80/240 (Part C)Bladder IO Naive-160/480 (Part C)NSCLC Prior IO-80/240 (Part C)MEL Prior IO - 80/240 (Part C)MEL Prior IO Rf-80/240 Q2W (Part D1 Coad)MEL Prior IO Rf-160/480 Q4W (Part D1 Coad)MEL Prior IO Rf-160/480 (Part D1 FDC)MEL Prior IO Rf-160/480 (Part D2)MEL 1L-160/480 (Part E)MEL 1L-480/480 (Part E)MEL Prior IO rf - 480/480 (Part E)
Part C, D1, D2, E - Duration of Response (DOR) Per Investigator15.3 (5.3 to 57.2)NA (3.7 to 67.9)NA (3.0 to 58.3)14.0 (3.7 to 59.8)53.4 (3.7 to 75.5)5.7 (2.4 to 62.6)16.8 (6.6 to 57.9)7.1 (5.6 to 8.6)NA (4.0 to 79.0)27.5 (1.0 to 75.7)31.5 (2.6 to 46.3)NA (5.5 to 70.1)18.9 (3.8 to 60.8)NA (6.5 to 60.7)NA (6.5 to 57.2)14.5 (2.0 to 57.0)
SecondaryPart C, D1 and D2: Progression-Free Survival (PFS) Rate Per Investigator

Progression Free Survival Rates up to 12 months is defined as the proportion of participants who achieve PFS up to 12 months. PFS for a participant is defined as the time from randomization date to the date of first objectively documented disease progression by investigator per response evaluation criteria in solid tumors (RECIST) v1.1 or death due to any cause, whichever occurs first. Based on Kaplan-Meier Estimates. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum during the study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

Time frame:
Up to 12 months
Reported as:
Number · proportion of participants
Part C, D1 and D2: Progression-Free Survival (PFS) Rate Per Investigator
proportion of participantsNSCLC IO Naive-80/240 (Part C)MEL 1L-80/240 (Part C)RCC IO Naive-80/240 (Part C)SCCHN IO Naive-80/240 (Part C)HCC IO Naive-80/240 (Part C)Gastric IO Naive-80/240 (Part C)Bladder IO Naive-160/480 (Part C)NSCLC Prior IO-80/240 (Part C)MEL Prior IO - 80/240 (Part C)MEL Prior IO Rf-80/240 Q2W (Part D1 Coad)MEL Prior IO Rf-160/480 Q4W (Part D1 Coad)MEL Prior IO Rf-160/480 (Part D1 FDC)MEL Prior IO Rf-160/480 (Part D2)
Part C, D1 and D2: Progression-Free Survival (PFS) Rate Per Investigator0.29 (0.12 to 0.49)0.47 (0.35 to 0.59)0.33 (0.15 to 0.53)0.20 (0.11 to 0.31)0.18 (0.10 to 0.29)0.06 (0.02 to 0.12)0.32 (0.18 to 0.48)0.16 (0.08 to 0.27)0.14 (0.09 to 0.20)0.17 (0.12 to 0.23)0.10 (0.05 to 0.18)0.21 (0.13 to 0.30)0.14 (0.09 to 0.21)
SecondaryNumber of Participants With Positive Anti Drug Antibodies

Blood samples were collected to assess anti-drug antibodies.

Time frame:
predose, and 4-hour post-dose of relatlimab on Cycle 1 Day 1 and Cycle 3 Day 1 (Each cycle consist of 28 days)
Reported as:
Count of participants · Participants
Number of Participants With Positive Anti Drug Antibodies
ParticipantsBMS-986016 (Relatlimab) Monotherapy 20 Milligram (mg) (Part A)BMS-986016 (Relatlimab) Monotherapy 80 Milligram (mgBMS-986016 (Relatlimab) Monotherapy 240 Milligram (mg) (Part A)BMS-986016 (Relatlimab) Monotherapy 800 Milligram (mg) (Part A/A1)Combination-Escalation-BMS-986016 (Relatlimab)/Nivolumab (20 mg/80 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (20 mg/240 mg (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (80 mg/240 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (160 mg/240 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (240 mg/240 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (160 mg/480 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (240 mg/480 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (320 mg/480 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (480 mg/480 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (960 mg/480 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (1440 mg/480 mg) (Part B)NSCLC IO Naive-80/240 (Part C)MEL 1L-80/240 (Part C)RCC IO Naive-80/240 (Part C)SCCHN IO Naive-80/240 (Part C)HCC IO Naive-80/240 (Part C)Gastric IO Naive-80/240 (Part C)Bladder IO Naive-160/480 (Part C)NSCLC Prior IO-80/240 (Part C)MEL Prior IO - 80/240 (Part C)MEL Prior IO Rf-80/240 Q2W (Part D1 Coad)MEL Prior IO Rf-160/480 Q4W (Part D1 Coad)MEL Prior IO Rf-160/480 (Part D1 FDC)MEL Prior IO Rf-160/480 (Part D2)MEL Prior IO rf - 480/480 (Part E)MEL 1L-160/480 (Part E)MEL 1L-480/480 (Part E)
relatlimab00002212010001051267191137214322050
Nivolumab————1012111003069218181644189204374
SecondaryPart A, A/A1, and B: Number of Participants With Clinically Relevant QT Prolongation

Abnormal electrocardiogram parameter included QT prolongation.

Time frame:
predose, and 4-hour post-dose of relatlimab on Cycle 1 Day 1 and Cycle 3 Day 1 (Each cycle consist of 28 days)
Reported as:
Count of participants · Participants
Part A, A/A1, and B: Number of Participants With Clinically Relevant QT Prolongation
ParticipantsBMS-986016 (Relatlimab) Monotherapy 20 Milligram (mg) (Part A)BMS-986016 (Relatlimab) Monotherapy 80 Milligram (mgBMS-986016 (Relatlimab) Monotherapy 240 Milligram (mg) (Part A)BMS-986016 (Relatlimab) Monotherapy 800 Milligram (mg) (Part A/A1)Combination-Escalation-BMS-986016 (Relatlimab)/Nivolumab (20 mg/80 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (20 mg/240 mg (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (80 mg/240 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (160 mg/240 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (240 mg/240 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (160 mg/480 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (240 mg/480 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (320 mg/480 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (480 mg/480 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (960 mg/480 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (1440 mg/480 mg) (Part B)
Part A, A/A1, and B: Number of Participants With Clinically Relevant QT Prolongation000000000000000
SecondaryMaximum Observed Concentration (Cmax) of BMS-986016 (Relatlimab)

Blood samples were collected for assessment of pharmacokinetic parameter of BMS-986016 (relatlimab).

Time frame:
Day 1 of Cycle 1 and 3
Reported as:
Geometric mean · microgram per milliliter (UG/ML)
Maximum Observed Concentration (Cmax) of BMS-986016 (Relatlimab)
microgram per milliliter (UG/ML)BMS-986016 (Relatlimab) Monotherapy 20 Milligram (mg) (Part A)BMS-986016 (Relatlimab) Monotherapy 80 Milligram (mgBMS-986016 (Relatlimab) Monotherapy 240 Milligram (mg) (Part A)BMS-986016 (Relatlimab) Monotherapy 800 Milligram (mg) (Part A/A1)Combination-Escalation-BMS-986016 (Relatlimab)/Nivolumab (20 mg/80 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (20 mg/240 mg (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (80 mg/240 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (160 mg/240 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (240 mg/240 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (160 mg/480 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (240 mg/480 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (320 mg/480 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (480 mg/480 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (960 mg/480 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (1440 mg/480 mg) (Part B)NSCLC IO Naive-80/240 (Part C)MEL 1L-80/240 (Part C)RCC IO Naive-80/240 (Part C)SCCHN IO Naive-80/240 (Part C)HCC IO Naive-80/240 (Part C)Gastric IO Naive-80/240 (Part C)Bladder IO Naive-160/480 (Part C)NSCLC Prior IO-80/240 (Part C)MEL Prior IO - 80/240 (Part C)MEL Prior IO Rf-80/240 Q2W (Part D1 Coad)MEL Prior IO Rf-160/480 Q4W (Part D1 Coad)MEL Prior IO Rf-160/480 (Part D1 FDC)MEL Prior IO Rf-160/480 (Part D2)MEL Prior IO rf - 480/480 (Part E)MEL 1L-160/480 (Part E)MEL 1L-480/480 (Part E)
Day 1 of Cycle 15.501 ± 2627.528 ± 3369.761 ± 32272.554 ± 295.762 ± 217.038 ± 2727.722 ± 7748.441 ± 5349.918 ± 3133.873 ± 1953.552 ± 3391.099 ± 23100.873 ± 25280.299 ± 27427.427 ± 1617.580 ± 2220.834 ± 3018.031 ± 2421.377 ± 3020.849 ± 3717.840 ± 3653.762 ± 1019.703 ± 2317.757 ± 26—48.214 ± 2444.735 ± 21————
Day 1 of Cycle 38.890 ± NA——527.000 ± NA8.138 ± 648.578 ± 1746.346 ± 3586.558 ± 1395.000 ± NA43.454 ± 7104.000 ± NA237.199 ± 108160.000 ± NA—595.364 ± 5543.135 ± 435.495 ± 1740.758 ± 3838.920 ± 2931.015 ± 3325.846 ± 282.188 ± 237.771 ± 2033.977 ± 39———————
SecondaryTime to Maximum Observed Concentration (Tmax) of BMS-986016 (Relatlimab)

Blood samples were collected for assessment of pharmacokinetic parameter of BMS-986016 (relatlimab).

Time frame:
Day 1 of Cycle 1 and 3 (Each cycle consist of 28 days).
Reported as:
Geometric mean · hours
Time to Maximum Observed Concentration (Tmax) of BMS-986016 (Relatlimab)
hoursBMS-986016 (Relatlimab) Monotherapy 20 Milligram (mg) (Part A)BMS-986016 (Relatlimab) Monotherapy 80 Milligram (mgBMS-986016 (Relatlimab) Monotherapy 240 Milligram (mg) (Part A)BMS-986016 (Relatlimab) Monotherapy 800 Milligram (mg) (Part A/A1)Combination-Escalation-BMS-986016 (Relatlimab)/Nivolumab (20 mg/80 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (20 mg/240 mg (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (80 mg/240 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (160 mg/240 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (240 mg/240 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (160 mg/480 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (240 mg/480 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (320 mg/480 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (480 mg/480 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (960 mg/480 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (1440 mg/480 mg) (Part B)NSCLC IO Naive-80/240 (Part C)MEL 1L-80/240 (Part C)RCC IO Naive-80/240 (Part C)SCCHN IO Naive-80/240 (Part C)HCC IO Naive-80/240 (Part C)Gastric IO Naive-80/240 (Part C)Bladder IO Naive-160/480 (Part C)NSCLC Prior IO-80/240 (Part C)MEL Prior IO - 80/240 (Part C)MEL Prior IO Rf-80/240 Q2W (Part D1 Coad)MEL Prior IO Rf-160/480 Q4W (Part D1 Coad)MEL Prior IO Rf-160/480 (Part D1 FDC)MEL Prior IO Rf-160/480 (Part D2)MEL Prior IO rf - 480/480 (Part E)MEL 1L-160/480 (Part E)MEL 1L-480/480 (Part E)
Day 1 of Cycle 13.173 ± 421.709 ± 929.700 ± 772.041 ± 682.988 ± 363.391 ± 1262.757 ± 463.007 ± 1385.599 ± 1053.585 ± 1332.240 ± 1722.047 ± 684.644 ± 1112.618 ± 2842.179 ± 1663.343 ± 293.391 ± 1021.840 ± 661.911 ± 622.534 ± 1342.578 ± 1332.312 ± 592.611 ± 462.191 ± 183—2.585 ± 492.095 ± 63————
Day 1 of Cycle 322.283 ± NA——4.000 ± NA1.983 ± 863.927 ± 1391.414 ± 475.005 ± 1314.000 ± NA5.083 ± 1302.950 ± NA1.762 ± 784.167 ± NA—2.045 ± 693.958 ± 14.455 ± 1193.928 ± 91.858 ± 632.515 ± 694.000 ± 04.457 ± 153.917 ± 162.940 ± 34———————
SecondaryArea Under the Concentration-time Curve in One Dosing Interval (AUCtau) of BMS-986016 (Relatlimab)

Blood samples were collected for assessment of pharmacokinetic parameter of BMS-986016 (relatlimab).

Time frame:
Day 1 of Cycle 1 and 3 (Each cycle consist of 28 days).
Reported as:
Geometric mean · hours*ug/mL
Area Under the Concentration-time Curve in One Dosing Interval (AUCtau) of BMS-986016 (Relatlimab)
hours*ug/mLBMS-986016 (Relatlimab) Monotherapy 20 Milligram (mg) (Part A)BMS-986016 (Relatlimab) Monotherapy 80 Milligram (mgBMS-986016 (Relatlimab) Monotherapy 240 Milligram (mg) (Part A)BMS-986016 (Relatlimab) Monotherapy 800 Milligram (mg) (Part A/A1)Combination-Escalation-BMS-986016 (Relatlimab)/Nivolumab (20 mg/80 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (20 mg/240 mg (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (80 mg/240 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (160 mg/240 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (240 mg/240 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (160 mg/480 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (240 mg/480 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (320 mg/480 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (480 mg/480 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (960 mg/480 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (1440 mg/480 mg) (Part B)NSCLC IO Naive-80/240 (Part C)MEL 1L-80/240 (Part C)RCC IO Naive-80/240 (Part C)SCCHN IO Naive-80/240 (Part C)HCC IO Naive-80/240 (Part C)Gastric IO Naive-80/240 (Part C)Bladder IO Naive-160/480 (Part C)NSCLC Prior IO-80/240 (Part C)MEL Prior IO - 80/240 (Part C)MEL Prior IO Rf-80/240 Q2W (Part D1 Coad)MEL Prior IO Rf-160/480 Q4W (Part D1 Coad)MEL Prior IO Rf-160/480 (Part D1 FDC)MEL Prior IO Rf-160/480 (Part D2)MEL Prior IO rf - 480/480 (Part E)MEL 1L-160/480 (Part E)MEL 1L-480/480 (Part E)
Day 1 of Cycle 1686.264 ± 403308.767 ± 2311848.262 ± 3538183.302 ± 16700.840 ± 32756.154 ± 383395.923 ± 207153.802 ± 357594.275 ± 196076.663 ± 3213473.538 ± 4619658.643 ± 3424397.911 ± 2868106.909 ± 18117532.665 ± 192374.750 ± 333237.956 ± 322550.155 ± 353040.426 ± 312548.992 ± 282584.823 ± 2711525.303 ± 102848.132 ± 282586.229 ± 26—9890.685 ± 2810641.828 ± 29————
Day 1 of Cycle 3———105538.444 ± NA1002.859 ± 841614.609 ± 426205.354 ± NA17913.840 ± 4521182.662 ± NA——34467.380 ± 4048155.384 ± NA—144555.686 ± 168838.930 ± NA8607.003 ± NA5325.430 ± NA8786.513 ± 322909.162 ± NA5374.646 ± NA23004.311 ± 47147.642 ± 286864.659 ± 53———————
SecondaryPart A/A1, B, C, D1, D2 and E: Trough Observed Concentration (Ctrough) of BMS-986016 (Relatlimab)

Blood samples were collected for assessment of pharmacokinetic parameter of BMS-986016 (relatlimab). Ctrough is defined as the lowest concentration of drug in the blood immediately before the next dose is administered. Ctrough was only assessed for arm Part A/A1, B, C, D1, D2 and E as pre-specified.

Time frame:
Day 1 of Cycle 3 (Each cycle consist of 28 days)
Reported as:
Geometric mean · ug/mL
Part A/A1, B, C, D1, D2 and E: Trough Observed Concentration (Ctrough) of BMS-986016 (Relatlimab)
ug/mLBMS-986016 (Relatlimab) Monotherapy 800 Milligram (mg) (Part A/A1)Combination-Escalation-BMS-986016 (Relatlimab)/Nivolumab (20 mg/80 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (20 mg/240 mg (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (80 mg/240 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (160 mg/240 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (240 mg/240 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (160 mg/480 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (240 mg/480 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (320 mg/480 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (480 mg/480 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (960 mg/480 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (1440 mg/480 mg) (Part B)NSCLC IO Naive-80/240 (Part C)MEL 1L-80/240 (Part C)RCC IO Naive-80/240 (Part C)SCCHN IO Naive-80/240 (Part C)HCC IO Naive-80/240 (Part C)Gastric IO Naive-80/240 (Part C)Bladder IO Naive-160/480 (Part C)NSCLC Prior IO-80/240 (Part C)MEL Prior IO - 80/240 (Part C)MEL Prior IO Rf-80/240 Q2W (Part D1 Coad)MEL Prior IO Rf-160/480 Q4W (Part D1 Coad)MEL Prior IO Rf-160/480 (Part D1 FDC)MEL Prior IO Rf-160/480 (Part D2)MEL Prior IO rf - 480/480 (Part E)MEL 1L-160/480 (Part E)MEL 1L-480/480 (Part E)
Part A/A1, B, C, D1, D2 and E: Trough Observed Concentration (Ctrough) of BMS-986016 (Relatlimab)215.000 ± NA1.283 ± 1071.597 ± 7314.176 ± 8338.174 ± 5046.600 ± NA2.656 ± 12640.690 ± 6319.239 ± 7521.400 ± NA98.000 ± NA212.230 ± 3413.929 ± 4513.317 ± 5715.192 ± 6015.138 ± 395.556 ± 9313.514 ± 468.364 ± 6412.621 ± 4716.119 ± 17315.239 ± 4810.084 ± 5467.329 ± 5513.201 ± 6348.055 ± 4410.842 ± 5963.314 ± 26
SecondaryPart A/A1, B, CTotal Body Clearance (CLT) of BMS-986016 (Relatlimab)

Blood samples were collected for assessment of pharmacokinetic parameter of BMS-986016 (relatlimab). CLT was only assessed for arm Part A/A1, B, C as pre-specified.

Time frame:
Day 1 of Cycle 3 (Each cycle consist of 28 days).
Reported as:
Geometric mean · mL/h
Part A/A1, B, CTotal Body Clearance (CLT) of BMS-986016 (Relatlimab)
mL/hBMS-986016 (Relatlimab) Monotherapy 800 Milligram (mg) (Part A/A1)Combination-Escalation-BMS-986016 (Relatlimab)/Nivolumab (20 mg/80 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (20 mg/240 mg (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (80 mg/240 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (160 mg/240 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (240 mg/240 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (160 mg/480 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (240 mg/480 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (320 mg/480 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (480 mg/480 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (960 mg/480 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (1440 mg/480 mg) (Part B)NSCLC IO Naive-80/240 (Part C)MEL 1L-80/240 (Part C)RCC IO Naive-80/240 (Part C)SCCHN IO Naive-80/240 (Part C)HCC IO Naive-80/240 (Part C)Gastric IO Naive-80/240 (Part C)Bladder IO Naive-160/480 (Part C)NSCLC Prior IO-80/240 (Part C)MEL Prior IO - 80/240 (Part C)
Part A/A1, B, CTotal Body Clearance (CLT) of BMS-986016 (Relatlimab)7.580 ± NA19.943 ± 8412.387 ± 4212.892 ± NA8.932 ± 4511.330 ± NANA ± NANA ± NA9.284 ± 409.968 ± NANA ± NA9.962 ± 169.051 ± NA9.295 ± NA15.022 ± NA9.105 ± 3227.499 ± NA14.885 ± NA6.955 ± 411.193 ± 3311.654 ± 39
SecondaryPart A/A1, B, C AUC Accumulation Index AI_AUC of BMS-986016 (Relatlimab)

Blood samples were collected for assessment of pharmacokinetic parameter of BMS-986016 (relatlimab). AUC Accumulation Index is a pharmacokinetic metric used to quantify how much a drug accumulates in the body after repeated dosing compared to a single dose. It is ratio of AUC Steady State (AUCss) and AUC1. AUCₛₛ is the area under the plasma concentration-time curve during a dosing interval at steady state (after repeated doses). AUC₁ is the area under the curve after a single dose. Only assessed for arm Part A/A1, B, C as pre-specified.

Time frame:
Day 1 of Cycle 3 (Each cycle consist of 28 days)
Reported as:
Geometric mean · Ratio of AUCss and AUC1
Part A/A1, B, C AUC Accumulation Index AI_AUC of BMS-986016 (Relatlimab)
Ratio of AUCss and AUC1BMS-986016 (Relatlimab) Monotherapy 800 Milligram (mg) (Part A/A1)Combination-Escalation-BMS-986016 (Relatlimab)/Nivolumab (20 mg/80 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (20 mg/240 mg (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (80 mg/240 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (160 mg/240 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (240 mg/240 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (160 mg/480 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (240 mg/480 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (320 mg/480 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (480 mg/480 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (960 mg/480 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (1440 mg/480 mg) (Part B)NSCLC IO Naive-80/240 (Part C)MEL 1L-80/240 (Part C)RCC IO Naive-80/240 (Part C)SCCHN IO Naive-80/240 (Part C)HCC IO Naive-80/240 (Part C)Gastric IO Naive-80/240 (Part C)Bladder IO Naive-160/480 (Part C)NSCLC Prior IO-80/240 (Part C)MEL Prior IO - 80/240 (Part C)
Part A/A1, B, C AUC Accumulation Index AI_AUC of BMS-986016 (Relatlimab)2.433 ± NANA ± NA1.825 ± 41.985 ± NA3.143 ± 36NA ± NANA ± NANA ± NA1.376 ± 541.606 ± NANA ± NA1.331 ± NA2.993 ± NA2.910 ± NA2.317 ± NA2.760 ± 321.525 ± NA2.131 ± NA1.877 ± 32.037 ± 332.550 ± 36

Adverse events

Collected over All-cause mortality was collected from first dose (Day 1) and up to approximately 89 months. SAEs and Other AEs were collected from first dose and within 135 days after last dose of study therapy (Up to approximately 82 months).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BMS-986016 (Relatlimab) Monotherapy 20 Milligram (mg) (Part A)5/5 (100%)5/5 (100%)5/5 (100%)
BMS-986016 (Relatlimab) Monotherapy 80 Milligram (mg) (Part A)3/4 (75%)3/4 (75%)4/4 (100%)
EBMS-986016 (Relatlimab) Monotherapy 240 Milligram (mg) (Part A)4/4 (100%)3/4 (75%)4/4 (100%)
BMS-986016 (Relatlimab) Monotherapy 800 Milligram (mg) (Part A)3/4 (75%)2/4 (50%)4/4 (100%)
Combination-Escalation-BMS-986016 (Relatlimab)/Nivolumab (20 mg/80 mg) (Part B)5/7 (71.4%)5/7 (71.4%)7/7 (100%)
Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (20 mg/240 mg (Part B)7/9 (77.8%)7/9 (77.8%)9/9 (100%)
Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (80 mg/240 mg) (Part B)6/8 (75%)6/8 (75%)8/8 (100%)
Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (160 mg/240 mg) (Part B)7/8 (87.5%)6/8 (75%)7/8 (87.5%)
Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (240 mg/240 mg) (Part B)6/8 (75%)7/8 (87.5%)8/8 (100%)
Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (160 mg/480 mg) (Part B)8/8 (100%)5/8 (62.5%)7/8 (87.5%)
MEL 1L-160/480 (Part E)27/77 (35.1%)49/77 (63.6%)74/77 (96.1%)
Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (240 mg/480 mg) (Part B)6/8 (75%)5/8 (62.5%)8/8 (100%)
Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (320 mg/480 mg) (Part B)6/8 (75%)6/8 (75%)8/8 (100%)
Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (480 mg/480 mg) (Part B)4/7 (57.1%)3/7 (42.9%)7/7 (100%)
MEL Prior IO rf - 480/480 (Part E)MEL 1L-480/480 (Part E)83/95 (87.4%)70/95 (73.7%)88/95 (92.6%)
MEL 1L-480/480 (Part E)33/77 (42.9%)47/77 (61%)74/77 (96.1%)
Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (960 mg/480 mg) (Part B)17/17 (100%)10/17 (58.8%)16/17 (94.1%)
Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (1440 mg/480 mg) (Part B)14/19 (73.7%)12/19 (63.2%)19/19 (100%)
BMS-986016 (Relatlimab) Expansion (NSCLC) 800 mg (Part A1)4/4 (100%)3/4 (75%)4/4 (100%)
BMS-986016 (Relatlimab) Expansion (RCC) 800 mg (Part A1)4/4 (100%)2/4 (50%)4/4 (100%)
MEL 1L-80/240 (Part C)37/66 (56.1%)38/66 (57.6%)56/66 (84.8%)
MEL Prior IO - 80/240 (Part C)117/151 (77.5%)98/151 (64.9%)124/151 (82.1%)
NSCLC Prior IO-80/240 (Part C)17/24 (70.8%)15/24 (62.5%)21/24 (87.5%)
NSCLC Prior IO-80/240 (Part C)-rf31/32 (96.9%)21/32 (65.6%)30/32 (93.8%)
NSCLC Prior IO-80/240 (Part C)-rl24/25 (96%)15/25 (60%)23/25 (92%)
SCCHN IO Naive-80/240 (Part C)57/65 (87.7%)44/65 (67.7%)62/65 (95.4%)
Gastric IO Naive-80/240 (Part C)80/94 (85.1%)69/94 (73.4%)89/94 (94.7%)
RCC IO Naive-80/240 (Part C)17/26 (65.4%)17/26 (65.4%)24/26 (92.3%)
HCC IO Naive-80/240 (Part C)49/63 (77.8%)49/63 (77.8%)61/63 (96.8%)
Bladder IO Naive-160/480 (Part C)29/37 (78.4%)28/37 (75.7%)30/37 (81.1%)
MEL Prior IO Rf-80/240 Q2W (Part D1 Coad)156/189 (82.5%)118/189 (62.4%)178/189 (94.2%)
MEL Prior IO Rf-160/480 Q4W (Part D1 Coad)71/83 (85.5%)58/83 (69.9%)77/83 (92.8%)
MEL Prior IO Rf-160/480 (Part D2)135/164 (82.3%)113/164 (68.9%)156/164 (95.1%)
MEL Prior IO Rf-160/480 (Part D1 FDC)64/82 (78%)49/82 (59.8%)77/82 (93.9%)
Most frequent serious events
Showing 10 of 499
Most frequent serious events
EventBMS-986016 (Relatlimab) Monotherapy 20 Milligram (mg) (Part A)BMS-986016 (Relatlimab) Monotherapy 80 Milligram (mg) (Part A)EBMS-986016 (Relatlimab) Monotherapy 240 Milligram (mg) (Part A)BMS-986016 (Relatlimab) Monotherapy 800 Milligram (mg) (Part A)Combination-Escalation-BMS-986016 (Relatlimab)/Nivolumab (20 mg/80 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (20 mg/240 mg (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (80 mg/240 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (160 mg/240 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (240 mg/240 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (160 mg/480 mg) (Part B)MEL 1L-160/480 (Part E)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (240 mg/480 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (320 mg/480 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (480 mg/480 mg) (Part B)MEL Prior IO rf - 480/480 (Part E)MEL 1L-480/480 (Part E)MEL 1L-480/480 (Part E)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (960 mg/480 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (1440 mg/480 mg) (Part B)BMS-986016 (Relatlimab) Expansion (NSCLC) 800 mg (Part A1)BMS-986016 (Relatlimab) Expansion (RCC) 800 mg (Part A1)MEL 1L-80/240 (Part C)MEL Prior IO - 80/240 (Part C)NSCLC Prior IO-80/240 (Part C)NSCLC Prior IO-80/240 (Part C)-rfNSCLC Prior IO-80/240 (Part C)-rlSCCHN IO Naive-80/240 (Part C)Gastric IO Naive-80/240 (Part C)RCC IO Naive-80/240 (Part C)HCC IO Naive-80/240 (Part C)Bladder IO Naive-160/480 (Part C)MEL Prior IO Rf-80/240 Q2W (Part D1 Coad)MEL Prior IO Rf-160/480 Q4W (Part D1 Coad)MEL Prior IO Rf-160/480 (Part D2)MEL Prior IO Rf-160/480 (Part D1 FDC)
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)5/53/41/41/43/75/94/82/85/82/811/772/81/82/730/957/772/177/192/42/412/6659/1516/248/328/2521/6544/947/2619/6314/3760/18923/8353/16424/82
TachycardiaCardiac disorders0/50/41/40/40/70/90/80/80/80/80/770/80/80/70/950/770/170/190/40/41/660/1510/240/320/250/650/940/260/630/370/1890/831/1640/82
Abdominal painGastrointestinal disorders0/51/40/40/41/71/91/80/81/80/81/770/80/80/73/952/770/170/190/40/40/661/1510/240/320/250/653/941/262/631/375/1891/835/1640/82
ConstipationGastrointestinal disorders0/50/40/40/40/70/91/80/80/80/80/770/80/80/70/950/770/170/190/41/40/661/1510/240/321/250/651/940/260/630/371/1890/833/1641/82
DiarrhoeaGastrointestinal disorders1/50/40/41/40/70/90/80/80/82/80/770/80/80/71/951/770/170/190/40/41/660/1510/241/320/250/651/940/261/631/374/1892/832/1641/82
DeathGeneral disorders0/50/41/40/40/70/90/80/80/80/80/770/80/80/71/950/770/170/190/40/40/661/1510/240/320/250/650/940/260/630/371/1890/830/1641/82
FatigueGeneral disorders0/51/40/40/40/70/90/80/81/80/80/770/80/80/70/953/770/170/190/40/40/660/1510/241/320/250/651/940/262/630/372/1890/830/1641/82
Non-cardiac chest painGeneral disorders0/50/40/40/40/70/90/80/80/80/80/770/80/80/70/950/770/170/191/40/40/661/1510/240/320/250/650/940/260/630/371/1891/830/1640/82
PyrexiaGeneral disorders0/50/40/40/40/70/90/80/80/80/80/770/80/80/73/951/770/172/190/41/42/666/1510/241/320/250/652/940/263/630/3710/1890/836/1640/82
Drug hypersensitivityImmune system disorders0/50/40/40/40/70/90/80/80/80/80/770/80/80/70/950/770/170/190/41/40/660/1510/240/320/250/650/940/261/630/370/1890/830/1640/82
Most frequent other events
Showing 10 of 402
Most frequent other events
EventBMS-986016 (Relatlimab) Monotherapy 20 Milligram (mg) (Part A)BMS-986016 (Relatlimab) Monotherapy 80 Milligram (mg) (Part A)EBMS-986016 (Relatlimab) Monotherapy 240 Milligram (mg) (Part A)BMS-986016 (Relatlimab) Monotherapy 800 Milligram (mg) (Part A)Combination-Escalation-BMS-986016 (Relatlimab)/Nivolumab (20 mg/80 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (20 mg/240 mg (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (80 mg/240 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (160 mg/240 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (240 mg/240 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (160 mg/480 mg) (Part B)MEL 1L-160/480 (Part E)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (240 mg/480 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (320 mg/480 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (480 mg/480 mg) (Part B)MEL Prior IO rf - 480/480 (Part E)MEL 1L-480/480 (Part E)MEL 1L-480/480 (Part E)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (960 mg/480 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (1440 mg/480 mg) (Part B)BMS-986016 (Relatlimab) Expansion (NSCLC) 800 mg (Part A1)BMS-986016 (Relatlimab) Expansion (RCC) 800 mg (Part A1)MEL 1L-80/240 (Part C)MEL Prior IO - 80/240 (Part C)NSCLC Prior IO-80/240 (Part C)NSCLC Prior IO-80/240 (Part C)-rfNSCLC Prior IO-80/240 (Part C)-rlSCCHN IO Naive-80/240 (Part C)Gastric IO Naive-80/240 (Part C)RCC IO Naive-80/240 (Part C)HCC IO Naive-80/240 (Part C)Bladder IO Naive-160/480 (Part C)MEL Prior IO Rf-80/240 Q2W (Part D1 Coad)MEL Prior IO Rf-160/480 Q4W (Part D1 Coad)MEL Prior IO Rf-160/480 (Part D2)MEL Prior IO Rf-160/480 (Part D1 FDC)
NauseaGastrointestinal disorders1/52/41/42/44/73/93/82/81/82/820/772/81/84/721/9524/776/176/193/40/415/6637/1513/247/325/259/6525/942/2616/634/3740/18920/8341/16421/82
FatigueGeneral disorders2/50/43/42/43/73/93/82/83/83/828/774/82/84/734/9540/777/176/192/40/423/6642/1516/2414/329/2513/6537/9412/2617/637/3748/18923/8348/16424/82
Back painMusculoskeletal and connective tissue disorders1/51/41/40/42/70/90/81/82/81/86/771/83/82/78/9516/773/172/191/43/413/6611/1514/241/325/251/6510/945/2610/632/3714/18913/8321/16411/82
DizzinessNervous system disorders0/51/40/43/40/70/91/84/82/81/85/772/82/81/72/9510/771/173/192/40/44/6612/1510/243/320/252/653/943/266/630/3711/1898/837/1643/82
HeadacheNervous system disorders0/50/40/43/41/71/91/82/82/81/815/771/81/81/710/9513/772/173/191/40/414/6622/1512/242/320/257/655/944/263/633/3719/18914/8324/1649/82
Decreased appetiteMetabolism and nutrition disorders3/51/41/41/44/71/92/83/84/82/816/771/81/82/714/959/775/175/192/40/414/6620/1513/246/322/2512/6520/945/2613/637/3737/18912/8324/16411/82
DiarrhoeaGastrointestinal disorders1/50/41/41/44/73/92/82/81/82/822/772/83/83/722/9520/773/177/190/40/417/6628/1514/2411/323/2512/6519/946/2623/639/3741/18917/8332/16416/82
PruritusSkin and subcutaneous tissue disorders0/51/40/40/40/70/92/82/81/82/820/772/83/84/717/9527/776/174/192/40/412/6624/1516/243/322/258/655/944/2610/638/3723/18918/8328/16411/82
ConstipationGastrointestinal disorders0/51/40/41/43/71/94/80/81/81/814/774/81/81/713/9517/775/174/190/41/49/6613/1516/245/323/2510/6526/941/2610/631/3734/18913/8326/16413/82
VomitingGastrointestinal disorders0/52/41/42/42/73/92/83/81/81/88/772/81/83/713/959/773/174/190/40/47/6616/1512/244/321/255/6516/942/269/634/3724/18910/8325/1646/82

Baseline characteristics

Age, Customized
Age, Customized(Participants)BMS-986016 (Relatlimab) Monotherapy 20 Milligram (mg) (Part A)BMS-986016 (Relatlimab) Monotherapy 80 Milligram (mg) (Part A)BMS-986016 (Relatlimab) Monotherapy 240 Milligram (mg) (Part A)BMS-986016 (Relatlimab) Monotherapy 800 Milligram (mg) (Part A/A1)Combination-Escalation-BMS-986016 (Relatlimab)/Nivolumab (20 mg/80 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (20 mg/240 mg (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (80 mg/240 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (160 mg/240 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (240 mg/240 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (160 mg/480 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (240 mg/480 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (320 mg/480 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (480 mg/480 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (960 mg/480 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (1440 mg/480 mg) (Part B)NSCLC IO Naive-80/240 (Part C)MEL 1L-80/240 (Part C)RCC IO Naive-80/240 (Part C)SCCHN IO Naive-80/240 (Part C)HCC IO Naive-80/240 (Part C)Gastric IO Naive-80/240 (Part C)Bladder IO Naive-160/480 (Part C)NSCLC Prior IO-80/240 (Part C)MEL Prior IO - 80/240 (Part C)MEL Prior IO Rf-80/240 Q2W (Part D1 Coad)MEL Prior IO Rf-160/480 Q4W (Part D1 Coad)MEL Prior IO Rf-160/480 (Part D1 FDC)MEL Prior IO Rf-160/480 (Part D2)MEL 1L-160/480 (Part E)MEL 1L-480/480 (Part E)MEL Prior IO rf - 480/480 (Part E)Total
< 65 years44466676765551015133320412768133395102444093464449857
>= 651006131212332741133624362624245687394271313346625
Sex: Female, Male
Sex: Female, Male(Participants)BMS-986016 (Relatlimab) Monotherapy 20 Milligram (mg) (Part A)BMS-986016 (Relatlimab) Monotherapy 80 Milligram (mg) (Part A)BMS-986016 (Relatlimab) Monotherapy 240 Milligram (mg) (Part A)BMS-986016 (Relatlimab) Monotherapy 800 Milligram (mg) (Part A/A1)Combination-Escalation-BMS-986016 (Relatlimab)/Nivolumab (20 mg/80 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (20 mg/240 mg (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (80 mg/240 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (160 mg/240 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (240 mg/240 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (160 mg/480 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (240 mg/480 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (320 mg/480 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (480 mg/480 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (960 mg/480 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (1440 mg/480 mg) (Part B)NSCLC IO Naive-80/240 (Part C)MEL 1L-80/240 (Part C)RCC IO Naive-80/240 (Part C)SCCHN IO Naive-80/240 (Part C)HCC IO Naive-80/240 (Part C)Gastric IO Naive-80/240 (Part C)Bladder IO Naive-160/480 (Part C)NSCLC Prior IO-80/240 (Part C)MEL Prior IO - 80/240 (Part C)MEL Prior IO Rf-80/240 Q2W (Part D1 Coad)MEL Prior IO Rf-160/480 Q4W (Part D1 Coad)MEL Prior IO Rf-160/480 (Part D1 FDC)MEL Prior IO Rf-160/480 (Part D2)MEL 1L-160/480 (Part E)MEL 1L-480/480 (Part E)MEL Prior IO rf - 480/480 (Part E)Total
Female321354253545338830712212711205966442679344038578
Male22392563534341411163619534267263792123395685433757904
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)BMS-986016 (Relatlimab) Monotherapy 20 Milligram (mg) (Part A)BMS-986016 (Relatlimab) Monotherapy 80 Milligram (mg) (Part A)BMS-986016 (Relatlimab) Monotherapy 240 Milligram (mg) (Part A)BMS-986016 (Relatlimab) Monotherapy 800 Milligram (mg) (Part A/A1)Combination-Escalation-BMS-986016 (Relatlimab)/Nivolumab (20 mg/80 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (20 mg/240 mg (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (80 mg/240 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (160 mg/240 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (240 mg/240 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (160 mg/480 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (240 mg/480 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (320 mg/480 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (480 mg/480 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (960 mg/480 mg) (Part B)Combo-esc--BMS-986016 (Relatlimab)/Nivolumab (1440 mg/480 mg) (Part B)NSCLC IO Naive-80/240 (Part C)MEL 1L-80/240 (Part C)RCC IO Naive-80/240 (Part C)SCCHN IO Naive-80/240 (Part C)HCC IO Naive-80/240 (Part C)Gastric IO Naive-80/240 (Part C)Bladder IO Naive-160/480 (Part C)NSCLC Prior IO-80/240 (Part C)MEL Prior IO - 80/240 (Part C)MEL Prior IO Rf-80/240 Q2W (Part D1 Coad)MEL Prior IO Rf-160/480 Q4W (Part D1 Coad)MEL Prior IO Rf-160/480 (Part D1 FDC)MEL Prior IO Rf-160/480 (Part D2)MEL 1L-160/480 (Part E)MEL 1L-480/480 (Part E)MEL Prior IO rf - 480/480 (Part E)Total
Hispanic or Latino100101000000001000012102313301021
Not Hispanic or Latino444875567478613111020410142810214252333383333541568
Unknown or Not Reported0003033214101471446225548642636107134494678444154893
08

Study locations

54 sites
  • Local Institution - 0043
    La Jolla, California 92093-0698, United States
  • Local Institution - 0053
    Aurora, Colorado 80045, United States
  • Local Institution - 0058
    Tampa, Florida 33612, United States
  • Local Institution - 0003
    Chicago, Illinois 60637, United States
  • Local Institution - 0048
    Niles, Illinois 60714, United States
  • Local Institution - 0004
    Baltimore, Maryland 21287, United States
  • Local Institution - 0001
    Boston, Massachusetts 02215, United States
  • Local Institution - 0011
    Detroit, Michigan 48201, United States
  • Local Institution - 0051
    Rochester, Minnesota 55905-0001, United States
  • Local Institution - 0044
    St Louis, Missouri 63110, United States
  • Local Institution - 0005
    New York, New York 10065, United States
  • Local Institution - 0002
    Portland, Oregon 97213, United States
  • Local Institution - 0047
    Allentown, Pennsylvania 18103, United States
  • Local Institution - 0010
    Pittsburgh, Pennsylvania 15232-1305, United States
  • Local Institution - 0057
    Dallas, Texas 75246, United States
  • Local Institution - 0045
    Houston, Texas 77030, United States
  • Local Institution - 0008
    Seattle, Washington 98109, United States
  • Local Institution - 0029
    North Sydney, New South Wales 2060, Australia
  • Local Institution - 0031
    Brisbane, Queensland 4120, Australia
  • Local Institution - 0039
    Southport, Queensland 4215, Australia
  • Local Institution - 0033
    Melbourne, Victoria 3000, Australia
  • Local Institution - 0032
    Nedlands, Western Australia 6009, Australia
  • Local Institution - 0023
    Vienna, 1090, Austria
  • Local Institution - 0024
    Vienna, 1090, Austria
  • Local Institution - 0049
    Toronto, Ontario M5G 2M9, Canada
  • Local Institution - 0050
    Québec, Quebec G1J 1Z4, Canada
  • Local Institution - 0028
    Copenhagen, 2100, Denmark
  • Local Institution - 0020
    Herlev, 2730, Denmark
  • Local Institution - 0021
    Helsinki, Uusimaa 00290, Finland
  • Local Institution - 0038
    Marseille, 13385, France
  • Local Institution - 0037
    Nantes, 44093, France
  • Local Institution - 0036
    Pierre-Bénite, 69495, France
  • Local Institution - 0026
    Toulouse, 31059, France
  • Local Institution - 0018
    Villejuif, 94800, France
  • Local Institution - 0007
    Essen, 45122, Germany
  • Local Institution - 0040
    Heilbronn, 74078, Germany
  • Local Institution - 0041
    Würzburg, 97080, Germany
  • Local Institution - 0014
    Milan, 20141, Italy
  • Local Institution - 0013
    Naples, 80131, Italy
  • Local Institution - 0035
    Padova, 35128, Italy
  • Local Institution - 0055
    Nagoya, Aichi-ken 4668560, Japan
  • Local Institution - 0059
    Sapporo, Hokkaido 0608543, Japan
  • Local Institution - 0054
    Sunto-gun, Shizuoka 4118777, Japan
  • Local Institution - 0052
    Chuo-ku, Tokyo 1040045, Japan
  • Local Institution - 0025
    Amsterdam, North Holland 1066 CX, Netherlands
  • Local Institution - 0019
    Oslo, 0379, Norway
  • Local Institution - 0015
    Barcelona, 08035, Spain
  • Local Institution - 0046
    Málaga, 29010, Spain
  • Local Institution - 0006
    Pamplona, 31008, Spain
  • Local Institution - 0017
    Lausanne, 1011, Switzerland
  • Local Institution - 0016
    Zurich, 8091, Switzerland
  • Local Institution - 0027
    London, Greater London NW1 2PG, United Kingdom
  • Local Institution - 0022
    London, Greater London SW3 6JJ, United Kingdom
  • Local Institution - 0034
    Manchester, M20 4BX, United Kingdom
09

References and documents

Publications

  • Ascierto PA, Tang H, Dolfi S, Nyakas M, Marie Svane I, Munoz-Couselo E, Grob JJ, Gomez-Roca CA, Chiarion-Sileni V, Peltola K, Larkin J, Melero I, Callahan M, Dummer R, Djidel P, Warad D, Reusser-Wolf D, Lipson EJ, Garnett-Benson C. Effect of prior and first-line immunotherapy on baseline immune biomarkers and modulation of the tumor microenvironment in response to nivolumab and relatlimab combination therapy in patients with melanoma from RELATIVITY-020. J Immunother Cancer. 2025 Feb 25;13(2):e009773. doi: 10.1136/jitc-2024-009773. PubMed 40010775 ↗
  • Ascierto PA, Lipson EJ, Dummer R, Larkin J, Long GV, Sanborn RE, Chiarion-Sileni V, Dreno B, Dalle S, Schadendorf D, Callahan MK, Nyakas M, Atkinson V, Gomez-Roca CA, Yamazaki N, Tawbi HA, Sarkis N, Warad D, Dolfi S, Mitra P, Suryawanshi S, Grob JJ. Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial. J Clin Oncol. 2023 May 20;41(15):2724-2735. doi: 10.1200/JCO.22.02072. Epub 2023 Feb 13. PubMed 36780608 ↗
  • Huuhtanen J, Kasanen H, Peltola K, Lonnberg T, Glumoff V, Bruck O, Dufva O, Peltonen K, Vikkula J, Jokinen E, Ilander M, Lee MH, Makela S, Nyakas M, Li B, Hernberg M, Bono P, Lahdesmaki H, Kreutzman A, Mustjoki S. Single-cell characterization of anti-LAG-3 and anti-PD-1 combination treatment in patients with melanoma. J Clin Invest. 2023 Mar 15;133(6):e164809. doi: 10.1172/JCI164809. PubMed 36719749 ↗
  • Nielsen M, Presti M, Sztupinszki Z, Jensen AWP, Draghi A, Chamberlain CA, Schina A, Yde CW, Wojcik J, Szallasi Z, Crowther MD, Svane IM, Donia M. Coexisting Alterations of MHC Class I Antigen Presentation and IFNgamma Signaling Mediate Acquired Resistance of Melanoma to Post-PD-1 Immunotherapy. Cancer Immunol Res. 2022 Oct 4;10(10):1254-1262. doi: 10.1158/2326-6066.CIR-22-0326. PubMed 35969233 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2013 to primary completion in May 2024, 126 months.

Results were first posted in Jan 2026, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2013
First posted
Oct 23, 2013
StartActual
Nov 5, 2013
Primary completionActual
May 22, 2024
CompletionActual
Feb 3, 2025
Results first posted
Jan 6, 2026
Last update
Apr 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01968109
Responsible party
Sponsor
First posted
Oct 23, 2013
Start date
Nov 5, 2013
Primary completion
May 22, 2024
Completion
Feb 3, 2025
Results posted
Jan 6, 2026
Last update
Apr 6, 2026

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Relatlimab

Start the discussion